A former adversary of the DEA and HHS now shapes federal drug reform as Deputy General Counsel, steering executive orders and clinical access.

Congress’s PATH Caucus outlines a federal–state roadmap to integrate psychedelic-assisted therapy into U.S. care with clinical safeguards, data tracking and provider standards.

From West Virginia to Hawaii, lawmakers are prepping for FDA-approved psilocybin drugs—not legalizing mushrooms. Here’s what’s moving, who’s behind it, and how it could affect DMV residents.

An overview of microdosing evidence for anxiety from the Microdosing Institute and its legal context across DC, Maryland, and Virginia.